Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Cancer Vaccines01:30

Cancer Vaccines

946
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
946
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

USP7 at PML Nuclear Bodies: A Protein Interaction Network Perspective.

International journal of molecular sciences·2026
Same author

Novel Small Molecule GLP-1R Agonists Based on 1<i>H</i>-Benzo[<i>d</i>]imidazole-5-Carboxylic Acid Scaffold.

Molecules (Basel, Switzerland)·2026
Same author

Structure and effective brightness of near-infrared fluorescent protein iRFP713/C15S/V254C complexed with phycocyanobilin.

The FEBS journal·2025
Same author

Dual organelle targeting for intra-organelle click: mitochondria and endoplasmic reticulum-directed benzothiophene-fused cycloalkyne probes.

Journal of materials chemistry. B·2025
Same author

PML Nuclear Bodies and Cellular Senescence: A Comparative Study of Healthy and Premature Aging Syndrome Donors' Cells.

Cells·2025
Same author

Pitfalls of Using ANS Dye Under Molecular Crowding Conditions.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jan 13, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K

Advancing CAR-T Therapy for Solid Tumors: From Barriers to Clinical Progress.

Sergei Smirnov1, Yuriy Zaritsky1, Sergey Silonov1

  • 1Institute of Cytology of the Russian Academy of Sciences, Tikhoretsky Ave. 4, St. Petersburg 194064, Russia.

Biomolecules
|October 29, 2025
PubMed
Summary

Chimeric antigen receptor (CAR)-T cell therapy shows promise for solid tumors. Next-generation strategies overcome challenges like immunosuppression and tumor heterogeneity, improving CAR-T cell efficacy in clinical trials.

Keywords:
CAR-TT-cellscellsclinicalefficacy nextgenerationimmunotherapysolidtumor

More Related Videos

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K

Related Experiment Videos

Last Updated: Jan 13, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Chimeric antigen receptor (CAR)-T cell therapy has transformed hematological cancer treatment.
  • Solid tumor treatment with CAR-T cells faces significant hurdles including immunosuppression, heterogeneity, and poor T cell persistence.

Purpose of the Study:

  • To review challenges in applying CAR-T cell therapy to solid tumors.
  • To evaluate clinical outcomes of current CAR constructs.
  • To highlight novel strategies for enhancing CAR-T cell efficacy in solid tumors.

Main Methods:

  • Examination of barriers to CAR-T cell efficacy in solid tumors.
  • Evaluation of clinical trial data for conventional CAR constructs.
  • Review of innovative next-generation CAR-T cell strategies.

Main Results:

  • Second- and third-generation CAR-T cells show limited efficacy in solid tumors.
  • Next-generation strategies like cytokine-armored CAR-T cells, logic-gated systems, and localized delivery show potential.
  • Advanced approaches include dominant-negative receptors (e.g., TGFβRII) and bispecific T cell engagers (BiTEs).

Conclusions:

  • Overcoming the immunosuppressive tumor microenvironment is crucial for CAR-T cell success.
  • Innovative CAR-T cell designs are essential to address antigen escape and improve persistence.
  • Next-generation CAR-T cell therapies offer promising avenues for treating solid tumors.